LBPH — Longboard Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Longboard Pharmaceuticals Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Longboard Pharmaceuticals Under Agreement H Lundbeck Required To Pay Co Reverse Termination Fee Of $158.9 Mln In Cash
U.S. RESEARCH ROUNDUP- Cadence Design Systems, Equity Bancshares, S&P Global
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Bausch + Lomb, SpartanNash, Hologic
U.S. STOCKS ON THE MOVE-Adobe, BigBear.ai, PG&E
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-B. Riley, crypto stocks, Longboard Pharmaceuticals
Longboard Pharma jumps on $2.6 bln Lundbeck buyout deal
Brief: Longboard Pharmaceuticals Says Lundbeck To Acquire Co In Strategic Deal
Denmark's Lundbeck to buy Longboard Pharma in $2.6 billion deal (updated)
Lundbeck to buy Longboard Pharma in $2.6 billion deal
Brief: Longboard Pharmaceuticals Initiates Phase 3 Deep Sea Study Evaluating Bexicaserin In Dravet Syndrome
Brief: Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule
Longboard Pharmaceuticals Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: Longboard Pharmaceuticals To Initiate Global Phase 3 Program Later This Year
U.S. RESEARCH ROUNDUP-Biomea Fusion, Enphase Energy, Perion Network
Brief: Longboard Pharmaceuticals Announces Positive Interim Results From The Open-Label Extension Of The Phase 1B/2A Pacific Study Evaluating Bexicaserin In Participants With Developmental And Epileptic Encephalopathies
Longboard Pharmaceuticals Inc expected to post a loss of 46 cents a share - Earnings Preview